AI Drug Firm Generate Biomedicines Raises $400M in IPO
AI-powered drug discovery firm Generate Biomedicines has successfully completed its IPO, raising $400 million. The listing, which attracted interest from pharma giants Amgen and Novartis, signals strong investor appetite for AI platforms with practical applications in specialized sectors like biotech.
Generate Biomedicines priced its 25 million shares at $16 each, the midpoint of its expected range, to hit the $400 million target. However, upon its Nasdaq debut under the ticker "GENB," the stock's price fell by more than 13% in initial trading. The company was founded in 2018 by Flagship Pioneering, the same venture firm that co-founded Moderna. It is led by CEO Mike Nally, who previously served as the Chief Marketing Officer for Merck. Prior to its IPO, Generate had already raised over $800 million in venture capital. Its pre-IPO valuation stood at $1.52 billion as of its Series B funding round in November 2021. The company's lead drug candidate, developed using its AI platform, is GB-0895 for the treatment of severe asthma, which entered Phase 3 clinical trials in January. A significant portion of the IPO proceeds, around $300 million, is allocated to advance this program. This was the largest biotech IPO of the year so far and contributed to February being the most active month for new biotech stock offerings in over a year. The average size of biotech IPOs in 2026 is also substantially larger than in recent years, signaling renewed investor confidence. The broader market for AI in drug discovery was estimated at $3.6 billion in 2024 and is projected to grow to nearly $50 billion by 2034. While investment is surging, a key challenge for the industry remains that no drug entirely discovered by AI has yet received full FDA approval.
